Biodesix CEO Scott Hutton Selected as One of Top 25 Biotech CEOs of 2021

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that The Healthcare Technology Report announced Chief Executive Officer, Scott Hutton, as one of the Top 25 Biotech CEOs of 2021.

The Healthcare Technology Report noted that the past twelve months, more than any other period in recent history, have showcased the outstanding talent, ingenuity, and determination of the world’s leading biotechnology executives and their organizations. Hutton was chosen from hundreds of nominees and was one of the executives that stood out for his continued dedication to patient care, and for significant contributions to the advancement of medicine.

“I am truly honored by this recognition, but must also extend the award to the entire Biodesix team who had the sense of urgency and resilience to achieve remarkable goals during the pandemic,” stated Mr. Hutton. “I am extremely proud of everything that the Biodesix team accomplished in 2020—our work to minimize the risk of COVID-19 infection rates resulted in new learnings and a stronger commitment to be the leader in fighting disease through accurate diagnostic testing with rapid results. The Biodesix team is incredibly energized for what lies ahead in 2021 and beyond.”

Find out more in the Biodesix press release.

Categories: Ecosystem News